Editas Medicine – Hot or Not


Editas Medicine (Nasdaq:EDIT) is a genome editing company which owns the main CRISPR Cas9 patents. It has a market cap of $692.7 million, but makes no profits and pays no dividends. Guest Joseph Busha from JM BUSHA Investment Group and resident expert Paul Theron from Vestact decide whether Editas Medicine is hot or not.

Partner Content

Absa commits to growing African trade with award-winning online platform

Absa launched its online trade finance portal, Trade Management Online, in 2019

Responsible banking in a post-COVID commodity market – Investing responsibly throughout the commodity value chain

While the alcohol sector invariably draws strong feelings from across the philosophical divide during Covid-19, what is indisputable...

A Cyber Pandemic May Be Next: How secure are you in the cloud?

The Coronavirus pandemic has influenced us in a more global way than the Cold War, affecting the environment, industry, finance, healthcare, leisure...

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox